EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care-Reference-Cited by-同舟云学术

EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care

Published:2023-12-18 Issue: Volume: Page:
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Hellings Peter W.¹²³^ORCID,Alobid Isam⁴⁵⁶,Anselmo‐Lima Wilma T.⁷,Bernal‐Sprekelsen Manuel⁸⁹^ORCID,Bjermer Leif¹⁰^ORCID,Caulley Lisa¹¹¹²¹³,Chaker Adam¹⁴^ORCID,Constantinidis Jannis¹⁵^ORCID,Conti Diego M.¹⁶^ORCID,De Corso Eugenio¹⁷^ORCID,Desrosiers Martin¹⁸,Diamant Zuzana¹⁰¹⁹²⁰²¹^ORCID,Gevaert Philippe³^ORCID,Han Joseph K.²²,Heffler Enrico²³²⁴^ORCID,Hopkins Claire²⁵,Landis Basile N.²⁶,Lourenco Olga²⁷²⁸^ORCID,Lund Valerie²⁹,Luong Amber U.³⁰^ORCID,Mullol Joaquim³¹^ORCID,Peters Anju³²^ORCID,Philpott Carl³³³⁴^ORCID,Reitsma Sietze³⁵^ORCID,Ryan Dermot³⁶^ORCID,Scadding Glenis³⁷,Senior Brent³⁸,Tomazic Peter Valentin³⁹^ORCID,Toskala Elina⁴⁰,Van Zele Thibaut³,Viskens An‐Sofie¹⁴¹^ORCID,Wagenmann Martin⁴²^ORCID,Fokkens W. J.³⁵^ORCID

Affiliation:

1. Department of Microbiology and Immunology, Allergy and Clinical Immunology Research unit KU Leuven Leuven Belgium

2. Clinical Department of Otorhinolaryngology, Head and Neck Surgery University Hospitals Leuven Leuven Belgium

3. Department of Otorhinolaryngology, Upper airways research laboratory Ghent University Ghent Belgium

4. Rhinology and Skull Base Unit, ENT Department, Hospital Clínic Universitat de Barcelona Barcelona Spain

5. Clinical and Experimental Respiratory Immunoallergy Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) Barcelona Spain

6. Center of Biomedical Research in Respiratory Diseases (CIBERES) Barcelona Spain

7. Division of Otorhinolaryngology, Department of Ophthalmology, Otorhinolaryngology, Head and Neck Surgery Ribeirao Preto Medical School‐University of Sao Paulo Brazil

8. Department of Otorhinolaryngology University of Barcelona Barcelona Spain

9. Department of Otorhinolaryngology Hospital Clinic Barcelona Barcelona Spain

10. Department of Respiratory Medicine & Allergology Institute for Clinical Science, Skane University Hospital, Lund University Lund Sweden

11. Department of Otolaryngology‐Head and Neck Surgery University of Ottawa Ottawa Ontario Canada

12. Clinical Epidemiology Program The Ottawa Hospital Research Institute Ottawa Ontario Canada

13. Institut for Klinisk Medicin Aarhus University Aarhus Denmark

14. Dept. of Otorhinolaryngology and Center for Allergy and Environment (ZAUM), TUM School of Medicine Klinikum rechts der Isar, Technical University of Munich Munich Germany

15. 1st Department of Otorhinolaryngology, Medical School, Faculty of Health Sciences Aristotle University of Thessaloniki Thessaloniki Greece

16. The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members Brussels Belgium

17. Otolaryngology, Head and Neck Surgery, Rhinology A. Gemelli University Hospital Foundation, IRCSS Rome Italy

18. Department of ORL‐HNS Université de Montréal Montreal Canada

19. Department of Microbiology Immunology & Transplantation, KU Leuven Catholic University of Leuven Leuven Belgium

20. Department of Respiratory Medicine, First Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

21. Department of Clinical Pharmacy & Pharmacology University in Groningen, University Medical Center Groningen Groningen Netherlands

22. Department of Otolaryngology & Head and Neck Surgery Eastern Virginia Medical School Virginia USA

23. Personalized Medicine Asthma and Allergy—IRCCS Humanitas Research Hospital Rozzano Italy

24. Department of Biomedical Sciences Humanitas University Pieve Emanuele Italy

25. Ear, Nose and Throat Department Guys and St. Thomas Hospital London UK

26. Rhinology‐Olfactology Unit, Department of Otorhinolaryngology Head and Neck Surgery University Hospital of Geneva Geneva Switzerland

27. FCS‐UBI, Faculty of Health Sciences University of Beira Interior Covilhã Portugal

28. CICS‐UBI, Health Sciences Research Centre University of Beira Interior Covilhã Portugal

29. Royal National Ear Nose and Eastman Dental Hospital London UK

30. Otolaryngology‐HNS McGovern Medical School of the University of Texas Health Science Center Houston Texas USA

31. Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, FRCB‐IDIBAPS Universitat de Barcelona, CIBERES Barcelona Spain

32. Division of Allergy and Immunology and Northwestern Sinus Center Northwestern University Feinberg School of Medicine Chicago Illinois USA

33. Rhinology & ENT Research Group, Norwich Medical School University of East Anglia Norwich UK

34. Norfolk & Waveney ENT Service James Paget and Norfolk & Norwich University Hospitals Norfolk UK

35. Department of Otorhinolaryngology Amsterdam University Medical Centres, University of Amsterdam Amsterdam The Netherlands

36. Allergy and Respiratory Research Group Usher Institute of Population Health Sciences and Informatics, University of Edinburgh Edinburgh UK

37. Royal National ENT Hospital, London and Division of Immunity and Infection University College London UK

38. Department of Otolaryngology/Head and Neck Surgery University of North Carolina Chapel Hill North Carolina USA

39. Department of General Otorhinolaryngology, H&N Surgery Medical University of Graz Graz Austria

40. Otolaryngology‐HNS Thomas Jefferson University Philadelphia Pennsylvania USA

41. Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium

42. Department of Otorhinolaryngology Universitätsklinikum Düsseldorf Dusseldorf Germany

Abstract

AbstractFollowing the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.15982

Reference76 articles.

1. European position paper on rhinosinusitis and nasal polyps 2020;Fokkens WJ;Rhinology,2020

2. EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis

3. International consensus statement on allergy and rhinology: rhinosinusitis 2021

4. Inflammatory Patterns in Upper Airway Disease in the Same Geographical Area may Change over Time

5. Chronic rhinosinusitis in Asia